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Abstract
Purpose: FASTR was designed to provide a compact treatment course for high-risk prostate cancer
patients but was discontinued because of excess toxicity. We present the results of FASTR-2,
which used a lower dose to the prostate (35 Gy vs 40 Gy), smaller posterior PTV margin (4 mm vs
5 mm) and omitted nodal radiation to lower the volumes of rectum receiving high and intermediate
doses compared with FASTR. Gastrointestinal (GI) and genitourinary (GU) toxicities at baseline,
6 weeks, 6 months, and 1 year and biochemical control rates are presented.
Methods and Materials: Eligibility included high-risk prostate cancer (cT3/4, prostate-specific
antigen >20 or Gleason Score 8), age 70 or refused standard treatment, and no evidence of
metastatic disease. Patients received 18 months of androgen deprivation therapy starting 2 months
before radiation. Clinical target volume was defined as prostate plus proximal 1-cm seminal
vesicles. PTV was a nonuniform expansion around clinical target volume (4 mm posteriorly, 5 mm
in all other directions). Volumetric arc therapy was used for treatment delivery (35 Gy delivered in
5 weekly fractions of 7 Gy each), and cone beam computed tomography with soft tissue matching
(no fiducial placement) was used for daily image guidance. Toxicity was assessed at 6 weeks,
6 months, and 1 year according to Common Toxicity Criteria.
Results: In the study, 30 patients were enrolled in FASTR-2 between 2015 and 2017. Two patients
were withdrawn owing to ineligibility after enrollment. One patient (3.7%) reported grade 2 GI
toxicity at 6 weeks. There was no reported grade 2 GI toxicity at 6 months or 1 year. There were
no reported episodes of rectal bleeding. Four patients (14.8%), 5 patients (17.9%), and 5 patients
(21.7%) reported grade 2 GU toxicity at 6 weeks, 6 months, and 1 year, respectively. There were
no reported cases of grade 3 GU toxicity. The most common toxicities were nocturia and urinary
frequency or urgency.
Sources of support: This work was supported by an unrestricted research grant from Sanofi-Aventis.
Disclosures: The authors declare that there is no conflict of interest.
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Conclusions: FASTR-2 was more tolerable than FASTR, with no grade 3 toxicities reported, in
keeping with expectations based on our previous FASTR analysis. Long-term follow-up is
necessary to ensure disease control and toxicity outcomes are comparable to conventional high-risk
treatment paradigms.
 2019 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Biochemical control and disease-free survival in high-risk
prostate cancer are improved with radical radiation com-
bined with adjuvant androgen deprivation compared with
either treatment alone.1,2 Although effective, this regimen
can be very demanding, especially on elderly or frail pa-
tients. Growing evidence suggests that prostate cancer has a
lower a-to-b ratio than most solid tumors and may benefit
from hypofractionation.3 Ultra-hypofractionation in the form
of stereotactic ablative radiation (SABR) has been shown to
be tolerable in the low- and intermediate-risk groups;4-8
however, the optimal protocol for treating high-risk pros-
tate cancer with SABR has yet to be established.
Short course radiation combined with androgen
deprivation therapy (ADT) was explored in the FASTR
trial,9 where patients received 12 months of ADT along
with radiation to the prostate (40 Gy/5 fractions delivered
weekly) and pelvic lymph nodes (25 Gy/5 fractions
delivered weekly). This study was discontinued after
accrual of 16 patients owing to an unacceptable rate of
acute and late toxicities including one grade 4 gastroin-
testinal (GI) toxicity. It was thought that the rate of
toxicity likely reflected the high rectal, small bowel, and
bladder doses secondary to the large prescription dose to
prostate and the inclusion of pelvic nodal irradiation.
The present study was designed with consideration of
these previous toxicities and used a lower dose to the
prostate (35 Gy/5 weekly fractions). Given the uncertainty in
survival benefit of pelvic nodal irradiation in prostate can-
cer,10,11 it was decided to omit pelvic lymph node irradia-
tion. Furthermore, recent evidence has shown equivalence of
18 months compared with 36 months of ADT,12 and we
decided to lengthen the duration of ADT to 18 months.
The aim of this phase I/II study is to prospectively
establish the safety and side effect profile of a novel
stereotactic, ultra-hypofractionated radiotherapy approach
to the prostate alone combined with 18 months of ADT
for the treatment of high-risk prostate cancer. The sec-
ondary outcome of biochemical disease-free survival is
also examined.
Methods and Materials
Patients were eligible for the study if they had at least
1 high-risk feature as described by the National
Comprehensive Cancer Network criteria for high-risk
prostate cancer (cT3/4, prostate-specific antigen [PSA]
>20 or Gleason Score  8 based on transrectal ultrasound
guided biopsy), no evidence of metastatic disease on
computed tomographic (CT) scan of the pelvis or on bone
scan, and were willing and able to comply with scheduled
visits, treatment plan, laboratory tests, and other study
procedures. Patients were considered for the trial if they
met the aforementioned criteria and were over the age of
70 years or declined standard treatment, with standard
treatment being defined as 70 Gy in 28 fractions to the
prostate and proximal seminal vesicles plus 48 Gy in 28
fractions to the pelvic nodes or 44 Gy in 22 fractions to
the prostate, seminal vesicles, and pelvic nodes with a
high-dose rate brachytherapy boost of 15 Gy to the
prostate. Patients were excluded from the study if they did
not meet the eligibility criteria outlined earlier; had
received prior pelvic radiotherapy or brachytherapy; were
taking anticoagulation; had a history of inflammatory
bowel disease, diverticulitis, or collagen vascular disease
(other than rheumatoid arthritis); had previous treatment
for malignancy (other than basal or squamous cell skin
cancer) within 3 years of prostate cancer diagnosis; or
were on ADT for >2 months before study enrollment.
Patients consenting for treatment received 18 months
of ADT. The preferred regimen was 3, 6-month lutei-
nizing hormone-releasing hormone (LHRH) agonist depot
injections (3- or 4-month depots also allowed). Four
weeks of antiandrogen therapy was given contempora-
neously with the initiation of LHRH agonist. Radiation
therapy began 2 months after ADT was initiated.
Patients were instructed on appropriate bowel and
bladder preparation for simulation and each treatment to
ensure an empty rectum and full bladder. Rectal spacers
were not utilized in this study. CT simulation allowed for
acquisition of images with a 3-mm slice thickness from L4
superiorly to the ischial tuberosities inferiorly. Resimula-
tion was allowed in the case of unrepresentative anatomy
(full rectum or empty bladder). The clinical target volume
(CTV) was defined as the prostate plus the proximal 1 cm
of the seminal vesicles (at a minimum, entire seminal
vesicles could be included if clinically involved). The PTV
was a nonuniform expansion around the CTV of 4 mm
posteriorly and 5 mm in all other directions. Magnetic
resonance imaging was not used for target delineation.
The following organs at risk were contoured in keeping
with the Radiation Therapy Oncology Group guidelines
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(www.rtog.org): anus (as a solid organ); rectum (as a solid
organ); bladder (as a solid organ); bilateral femoral heads
and proximal femurs to the level of the ischial tuberosities;
penile bulb; and small bowel. Volumetric-modulated arc
therapy was planned with the dose volume histogram
(DVH) constraints outlined in Table 1, where the DVH
constraints from the original FASTR trial were also listed
for comparison. As shown in Table 1, the DVH constraints
for organs at risk (OARs) are more restrictive in the
FASTR-2 trial than those in the FASTR trial. The tighter
DVH constraints for OARs were the results of lower
prescription dose (35 Gy instead of 40 Gy), smaller target
volume (not including pelvic nodes), smaller posterior
PTV margin (4 mm instead of 5 mm), and the analysis of
the previous FASTR trial.13
Treatments were delivered in 5 fractions, 1 fraction per
week for 5 weeks. All plans were verified in phantom
before the first treatment fraction with a tolerance of 95%
passing rate using gamma parameters, 3% in dose dif-
ference, and 3 mm for distance to agreement.
Patients received treatment on a linear accelerator with
cone beam CT (CBCT) capabilities. CBCT was obtained
before each treatment with automatic and manual soft
tissue registration to the prostate. The attending radiation
oncologist was responsible for viewing and approving the
registration for the first fraction of treatment.
Patients were assessed at baseline and at 6 weeks after
treatment. They were assessed at 6 monthly intervals
thereafter until 3 years, then yearly. Assessments included
measurements of toxicity using the Common Toxicity
Criteria version 4.0. Measurements of prostate-specific
antigen (PSA) and testosterone were checked at baseline
and at each of the postradiotherapy visits. Liver function
tests were checked at baseline, 6 weeks, and 6 months
after treatment. The study was approved by the university
Research Ethics Board.
The primary outcome was the incidence of grade 3
genitourinary (GU) and GI toxicity at 6 weeks, 6 months,
and 1 year. Secondary endpoints were biochemical
disease-free survival at 1, 2, and 3 years.
An independent data safety monitoring committee
reviewed the toxicity data for the initial 15 patients
enrolled after 6 months of follow-up.
Dose-volume histogram (DVH) values for FASTR and
FASTR-2 were compared using the Wilcoxon signed-
rank test. All analyses were performed using R Studio
(version 3.4.1). P values < .05 were considered statisti-
cally significant.
Results
Thirty patients were enrolled in the study between
March 2015 and August 2017. Two patients were with-
drawn from the study before treatment: 1 patient was
found to have pelvic nodal involvement after enrollment
and 1 patient had significant stool burden resulting in poor
reproducibility of anatomy. Of the 30 patients enrolled, 26
were 70 years and 4 were <70 years but declined
standard therapy. All patients had high-risk prostate
cancer with a PSA >20 ng/mL (n Z 12), Gleason
grade  8 (n Z 17), or clinical T3 or T4 disease (n Z 6).
Baseline characteristics are summarized in Table 2. All 28
patients that received treatment were treated according to





D95 Z 35 Gy D95 Z 40 Gy
D5 Z 33 Gy D5 Z 42 Gy
Dmax Z 38 Gy Dmax Z 43 Gy
PTV nodes D95 Z 25 Gy
D5 Z 28 Gy
Dmax Z 41 Gy
(within 1 cm of
high dose
volume)
Dmax Z 28 Gy
(outside 1 cm of
high dose
volume)
Bladder V26  50% V29  50%
V31  30% V35  30%
Rectum V20  60% V27  50%
V24  50% V35  20%
V32  10%
V35  2 mL
Small bowel V27.5  2 mL V27.5  2 mL
V25  190 mL V25  190 mL
Table 2 Baseline patient characteristics
Variable Total (n Z 30)












Risk category (based on NCCN
criteria)
High 23 (76.6%)
Very high 7 (23.3%)
Abbreviations: NCCN Z National Comprehensive Cancer Network;
PSA Z prostate-specific antigen.
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protocol. Median follow-up was 28 months (range, 12-44)
from the start of radiation.
In addition, 27 patients were available for toxicity
analysis at 6 weeks, 28 patients were available for anal-
ysis at 6 months, and 23 patients were available for
analysis at 1 year. No grade 3 or higher toxicities were
reported at any time point. At baseline, 1 patient (3.5%)
had moderate to severe nocturia and no patients had
moderate or severe gastrointestinal symptoms. Five pa-
tients (18.5%) experienced grade 2 toxicity at 6 weeks
after completion of radiation treatment (4 GU and 1 GI).
Five patients (17.9%) experienced grade 2 GU toxicity at
6 months, and 5 patients (21.7%) experienced grade 2 GU
toxicity at 1 year. There were no instances of grade 2 or
higher GI toxicity at 6 months or 1 year. Toxicity data is
summarized in Table 3. The most common toxicities
experienced were nocturia and urinary frequency or ur-
gency. There were no reported episodes of rectal bleeding
at any time point. Of the 23 patients seen at 1-year follow-
up, there were no cases of biochemical failure (mean PSA
0.05, maximum PSA 0.23).
Dosimetric constraints to OARs were met in all pa-
tients. The rectal maximum dose (D1), D20, and D50,
decreased from 40.7 Gy, 29.6 Gy, and 20.8 Gy in FASTR
to 35.0 Gy, 22.2 Gy and 11.1 Gy in FASTR-2 (P < .001),
respectively. The bladder maximum dose (D1), D20 and
D50, decreased from 40.9 Gy, 28.1 Gy, and 21.5 Gy in
FASTR to 35.7 Gy, 15.7 Gy, and 6.3 Gy in FASTR-2
(P < .001), respectively. Dosimetric results are compared
in Table 4 between the FASTR-2 and the FASTR trials.
Discussion
FASTR-2 was well tolerated, with no reported grade 3
or higher toxicities. This is in keeping with expectations
based on our analysis of the FASTR trial where it was
found that higher relative dose volumes to the rectum
(V20-40 Gy) was most strongly associated with rectal
bleeding.13 The FASTR-2 protocol was created with
stricter dosimetric constraints to the rectum and bladder
compared with the original FASTR protocol, in addition
to a lower prescribed dose to the PTV and elimination of
nodal irradiation. With the implementation of these
changes, there were no reported instances of rectal
bleeding or of intermediate or late grade 2 or higher GI
toxicities and only 1 reported instance of early grade 2 GI
toxicity.
The majority of prostate SABR studies have looked at
the role of ultra-hypofractionation in low or intermediate
risk prostate cancer; only a few studies have looked at the
role of SABR in patients with high-risk prostate cancer.
The recently published results from the phase 3, ran-
domized HYPO-RT-PC trial14 show noninferiority of
ultra-hypofractionated radiation compared with conven-
tional fractionation for patients with intermediate and
high-risk prostate cancer.14 Patients in the conventional
fractionation arm (n Z 602) received 78 Gy in 39 frac-
tions and patients in the ultra-hypofractionated arm
(n Z 598) received 42.7 Gy in 7 fractions delivered every
other day. Treatment in both arms was prescribed to the
Table 3 Summary of GU and GI toxicities
Baseline (n Z 28) 6 weeks (n Z 27) 6 months (n Z 28) 1 year (n Z 23)
Grade 1 GU 10 (35.7%) 15 (55.5%) 17 (60.7%) 15 (65.2%)
Grade 2 GU 1 (3.6%) 4 (14.8%) 5 (17.9%) 5 (21.7%)
Grade 1 GI 3 (10.7%) 8 (29.6%) 12 (42.9%) 9 (39.1%)
Grade 2 GI 0 1 (3.7%) 0 0
Abbreviations: GI Z gastrointestinal; GU Z genitourinary.
Table 4 Dosimetric outcomes for FASTR-2 and FASTR
FASTR-2 FASTR9
Mean Range Mean Range P Value
D95 prostate and proximal SV 35.2 Gy 33.7-35.9 Gy 40.2 Gy 40.0-40.7 Gy <.001
V100 prostate and proximal SV 96.4% 83.8-101.7% 96.3% 95.0-100.0% .376
D95 nodes 25.2 Gy 24.7-25.4 Gy n/a
V100 nodes 96.8% 85.1-100.0% n/a
D1 rectum 35.0 Gy 31.2-36.1 Gy 40.7 Gy 39.7-41.5 Gy <.001
D20 rectum 22.2 Gy 9.4-32.9 Gy 29.6 Gy 24.1-39.2 Gy <.001
D50 rectum 11.1 Gy 4.0-22.4 Gy 20.8 Gy 15.3-25.2 Gy <.001
D1 bladder 35.7 Gy 30.8-36.4 Gy 40.9 Gy 37.6-42.0 Gy <.001
D20 bladder 15.7 Gy 2.5-33.3 Gy 28.1 Gy 23.5-36.5 Gy <.001
D50 bladder 6.3 Gy 0.7-22.2 Gy 21.5 Gy 15.3-26.2 Gy <.001
SV Z Seminal vesicles.
Advances in Radiation Oncology: OctobereDecember 2019 FASTR-2: preliminary results and analysis 671
prostate only with a 7-mm PTV expansion using fiducial
markers for image guidance. Five year biochemical and
clinical control rates were 83.8% and 83.7% for the
conventional fractionation and ultra-hypofractionation
arms, respectively. Furthermore, physician reported late
grade 2 or higher toxicity was not significantly different
between the 2 arms.
Two previous prospective phase I/II trials have
explored the role of SABR to prostate and elective
nodal volumes. Both the SATURN (Stereotactic Abla-
tive Radiotherapy Including Regional Lymph Node
Irradiation) and FASTR trials prescribed 40 Gy in 5
fractions to the prostate and 25 Gy in 5 fractions to the
regional lymph nodes; however, these 2 studies had
very different toxicity outcomes.9,15 FASTR was
terminated during phase I owing to excess late GI
toxicities; whereas within SATURN, minimal GI tox-
icities were noted. A detailed dosimetric analysis of the
2 studies allowed for identification of a correlation
between higher dose (20 Gy/5 fractions) volumes to
the rectum and GI toxicity.13 FASTR defined the high-
dose volume to include the prostate and the proximal
1 cm of seminal vesicle, with a 5-mm expansion from
CTV to PTV. SATURN, on the other hand, defined
their high dose volume to include only the prostate and
used fiducial markers to allow for a 3-mm expansion
from CTV to PTV. Furthermore, in FASTR, radiation
was prescribed such that 95% of the high-dose PTV
received at least 40 Gy; whereas in SATURN, radiation
was prescribed such that 99% of the high-dose PTV
received at least 33.25 Gy. These variations in protocol
are thought to explain the increased rectal dose and
increased rectal toxicity experienced in the FASTR
trial.
Other prospective trials have explored the role of
SABR for localized high-risk prostate cancer either as
monotherapy or in combination with external beam
radiotherapy to pelvic nodes.16-19 Only one of these trials
had any reported grade 3 or higher toxicity, with 2 of 18
patients with high-risk prostate cancer treated with EBRT
to the pelvic nodes in addition to SBRT boost to the
prostate experiencing grade 3 GU toxicity.17 The 2 studies
with the longest follow-up reported biochemical disease
free survival of 65% at 8 years16 and 91.9% at 4 years.18
In all of these studies, fiducial markers were used for
image guidance.
The role of ADT in combination with SABR has not
been well established. Extrapolation from ablative dosing
with brachytherapy for high-risk prostate cancer does
indicate that there may be less benefit to ADT than con-
ventional radiotherapy.20 Current guidelines continue to
recommend ADT in addition to radiation for patients with
high-risk prostate cancer, although it is unclear whether
this should apply.21 It should be acknowledged that ADT
may increase late GI toxicities.22
Limitations of this study include small sample size and
lack of randomized control data. The dose prescription used
in this study was 35 Gy in 5 fractions prescribed to 95% of
the PTV. Although this is a lower dose than reported in
similar trials, this dose is in keeping with the recently pub-
lished American Society for Radiation Oncology (ASTRO)/
American Society of Clinical Oncology (ASCO)/American
Urological Association (AUA) guidelines on hypofractio-
nated radiotherapy for localized prostate cancer, which
recommends 35 to 36.25 Gy in 5 fractions for ultra-
hypofractionated EBRT regimens as doses higher than this
are associated with increased risk of late toxicity.23 Pelvic
nodes were not included in the treatment field in this study;
however, the role of nodal irradiation in high-risk prostate
cancer is controversial. The long-term results of the
GETUG-01 and RTOG-9413 trials did not show benefit of
pelvic nodal irradiation for high-risk prostate cancer patients
who were also receiving adjuvant ADT.10,11 This protocol
uses a larger PTV expansion than some similar trials
because image guidance was achieved using CBCT without
the use of fiducial markers. Fiducial markers have been used
in the vast majority of trials studying the use of SABR for
prostate cancer; however, it has a number of limitations,
including the requirement for local expertise in placing the
markers, risks of infection associated with the transperineal
procedure, and possibility of marker migration resulting in
unreliable image registration and, as such, are not neces-
sarily feasible for all centers or all patients. Biochemical
control was achieved in all patients at 1-year follow-up;
however, all patients remained on ADT at this timepoint,
and therefore longer follow-up is required to determine
whether the efficacy of this treatment regimen is comparable
to standard treatment for high-risk prostate cancer.
Benefits of the FASTR-2 protocol include a weekly
fractionation schedule with only 5 fractions, making this
regimen especially appealing for frail patients or patients
travelling a long distance for treatment. Prostate directed
radical radiation has been shown to improve overall survival
in men with low-volume metastatic disease treated with
concurrent ADT.24,25 The FASTR-2 treatment regimen
should be similarly well tolerated in this patient population,
and the small number of fractions would be desirable in a
patient population with known metastatic disease.
Conclusion
The FASTR-2 protocol allows for safe delivery of
ultra-hypofractionated radiotherapy to the prostate and
seminal vesicles in patients with high-risk prostate cancer
without the use of fiducial markers and using a weekly
treatment schedule, which is more convenient for some
patients. Long term follow-up is required to ensure dis-
ease control and toxicity outcomes are comparable to
conventional high-risk treatment paradigms.
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